Gotowa bibliografia na temat „Repurposed drug”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „Repurposed drug”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Artykuły w czasopismach na temat "Repurposed drug"
Al Khzem, Abdulaziz H., Mohamed S. Gomaa, Mansour S. Alturki, Nada Tawfeeq, Mohammad Sarafroz, Shareefa M. Alonaizi, Alhassan Al Faran, Laela Ahmed Alrumaihi, Fatimah Ahmed Alansari i Abdullah Abbas Alghamdi. "Drug Repurposing for Cancer Treatment: A Comprehensive Review". International Journal of Molecular Sciences 25, nr 22 (19.11.2024): 12441. http://dx.doi.org/10.3390/ijms252212441.
Pełny tekst źródłaAleksic, Sandra. "REPURPOSED FOR AGING". Innovation in Aging 8, Supplement_1 (grudzień 2024): 139–40. https://doi.org/10.1093/geroni/igae098.0449.
Pełny tekst źródłaAraújo, Diana, Eduarda Ribeiro, Irina Amorim i Nuno Vale. "Repurposed Drugs in Gastric Cancer". Molecules 28, nr 1 (30.12.2022): 319. http://dx.doi.org/10.3390/molecules28010319.
Pełny tekst źródłaOlgen, Sureyya, i Lakshmi P. Kotra. "Drug Repurposing in the Development of Anticancer Agents". Current Medicinal Chemistry 26, nr 28 (25.10.2019): 5410–27. http://dx.doi.org/10.2174/0929867325666180713155702.
Pełny tekst źródłaMoura, Catarina, Ana Salomé Correia, Mariana Pereira, Eduarda Ribeiro, Joana Santos i Nuno Vale. "Atorvastatin and Nitrofurantoin Repurposed in the Context of Breast Cancer and Neuroblastoma Cells". Biomedicines 11, nr 3 (15.03.2023): 903. http://dx.doi.org/10.3390/biomedicines11030903.
Pełny tekst źródłaProsdocimi, Marco, Cristina Zuccato, Lucia Carmela Cosenza, Monica Borgatti, Ilaria Lampronti, Alessia Finotti i Roberto Gambari. "A Rational Approach to Drug Repositioning in β-thalassemia: Induction of Fetal Hemoglobin by Established Drugs". Wellcome Open Research 7 (23.06.2022): 150. http://dx.doi.org/10.12688/wellcomeopenres.17845.2.
Pełny tekst źródłaProsdocimi, Marco, Cristina Zuccato, Lucia Carmela Cosenza, Monica Borgatti, Ilaria Lampronti, Alessia Finotti i Roberto Gambari. "A Rational Approach to Drug Repositioning in β-thalassemia: Induction of Fetal Hemoglobin by Established Drugs". Wellcome Open Research 7 (17.08.2022): 150. http://dx.doi.org/10.12688/wellcomeopenres.17845.3.
Pełny tekst źródłaProsdocimi, Marco, Cristina Zuccato, Lucia Carmela Cosenza, Monica Borgatti, Ilaria Lampronti, Alessia Finotti i Roberto Gambari. "A Rational Approach to Drug Repositioning in β-thalassemia: Induction of Fetal Hemoglobin by Established Drugs". Wellcome Open Research 7 (12.05.2022): 150. http://dx.doi.org/10.12688/wellcomeopenres.17845.1.
Pełny tekst źródłaStone, Heather, Mili Duggal, Leonard Sacks i Mayurika Ghosh. "1380. Safety of Repurposed Drugs for Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: An Analysis of Adverse Events Reported in the Literature". Open Forum Infectious Diseases 6, Supplement_2 (październik 2019): S501. http://dx.doi.org/10.1093/ofid/ofz360.1244.
Pełny tekst źródłaJayaram, Saravanan, Emdormi Rymbai, Deepa Sugumar i Divakar Selvaraj. "Drug Repurposing: A Paradigm Shift in Drug Discovery". INTERNATIONAL JOURNAL OF APPLIED PHARMACEUTICAL SCIENCES AND RESEARCH 5, nr 04 (30.06.2020): 60–68. http://dx.doi.org/10.21477/ijapsr.5.4.2.
Pełny tekst źródłaRozprawy doktorskie na temat "Repurposed drug"
Olayanju, Olatunde. "Efficacy and safety of novel and repurposed drugs for the treatment of drug-resistant tuberculosis". Doctoral thesis, Faculty of Health Sciences, 2020. http://hdl.handle.net/11427/32322.
Pełny tekst źródłaHervieu, Laura. "Dévelοppement et évaluatiοn de nanοvecteurs pοur l'administratiοn οrale de fénοldοpam en vue du traitement de la pοlykystοse rénale autοsοmique dοminante". Electronic Thesis or Diss., Normandie, 2024. http://www.theses.fr/2024NORMR100.
Pełny tekst źródłaAutosomal dominant polycystic kidney disease (ADPKD) is a hereditary disorder characterized by the presence of cysts in the kidneys and associated cardiovascular complications. It is responsible for about 5 to 10% of end-stage renal failure cases. Currently, there is no treatment available for the therapeutic management of renal and cardiovascular complications of ADPKD. The disease is characterized by dysfunction of polycystins in the cilia of vascular endothelial and renal tubular cells, which play a role in detecting mechanical stimuli. Numerous studies have highlighted the therapeutic potential of stimulating dopamine type 5 receptors (D5), which can restore the mechanosensitivity of endothelial cells. Among dopamine agonists, fenoldopam stands out due to its selectivity for D5 receptors. However, its physicochemical properties, particularly its short half-life and sensitivity to metabolism, make it poorly suited for oral administration, a preferred route for chronic diseases. In this context, fenoldopam has been formulated into nanoemulsions and liposomes. Both formulations allowed for the encapsulation of fenoldopam. While the nanoemulsions showed instability in biomimetic media, confirmed by the lack of improvement in the pharmacokinetic profile, the liposomes demonstrated greater stability. They also modified the fate of fenoldopam compared to its free form in solution after oral administration, suggesting the possibility of achieving prolonged release
Hou, Chun-Li, i 侯君里. "The pan-Aurora kinase inhibitor tozasertib as a repurposed drug for Mycn-amplified neuroblastoma". Thesis, 2016. http://ndltd.ncl.edu.tw/handle/91763913618808780304.
Pełny tekst źródłaChung, Feng-Hsiang, i 鍾豐翔. "A Framework for Searching for Repurposed Drug Compounds for Systems Treatment of Complex Diseases: An Application to Colorectal Adenocarcinoma". Thesis, 2014. http://ndltd.ncl.edu.tw/handle/8249tv.
Pełny tekst źródła國立中央大學
系統生物與生物資訊研究所
102
Drug repurposing has become an increasingly attractive approach to drug development owing to the ever-growing cost of new drug discovery and frequent withdrawal of successful drugs caused by side effect issues. Cancer is now recognized as is a systems disease caused by the breakdown of a large part of the cellular system, not just of the failure of one or two genes. Therefore, one cannot expect cancer to be effectively treated by one or a few single-target drugs. Here, we devised Functional Module Connectivity Map (FMCM) for the discovery of repurposed drug compounds for systems treatment of complex diseases, and applied it to colorectal adenocarcinoma. FMCM used multiple functional gene modules to query the Connectivity Map (CMap). The functional modules were built around hub genes identified, through the Gene Selection by Trend-of-disease-Progression (GSToP) procedure, from condition-specific gene-gene interaction networks constructed from sets of cohort gene expression microarrays. The formulated drug compounds were restricted to drugs exhibiting predicted minimal intracellular harmful side effects. Genes selected by GSToP had a much higher cancer gene hit rate (~50%) than that obtained by eBayes and SAM (~20%). We tested FMCM against the common practice of selecting drugs by using a single set of individual genes to query CMap (IGCM), and found that FMCM have higher robustness, accuracy, and reproducibility in identifying known anti-cancer agents. Among the 46 drugs selected by FMCM for colorectal adenocarcinoma, 65% had literature support for association with anti-cancer activities, and three drugs predicted to have adverse harmful effects on cancers had also been reported. In cell viability tests, we validated four candidate drugs: GW-8510, etacrynic acid, ginkgolide A, and 6-azathymine, as having high inhibitory activities against cancer cells. Through microarray experiments we confirmed the novel functional links predicted for three candidate drugs: phenoxybenzamine (broad effects), GW-8510 (cell cycle), and imipenem (immune system). We expect FMCM can be widely applied to repurposed drug discovery for systems treatment of other complex diseases.
Pacheco, Mariana Carvalho Dias Brutt. "Demethylation of the epigenetically silenced androgen receptor gene by a repurposed drug in castration-resistant prostate cancer cell lines". Master's thesis, 2019. https://hdl.handle.net/10216/124744.
Pełny tekst źródłaPacheco, Mariana Carvalho Dias Brutt. "Demethylation of the epigenetically silenced androgen receptor gene by a repurposed drug in castration-resistant prostate cancer cell lines". Dissertação, 2019. https://hdl.handle.net/10216/124744.
Pełny tekst źródłaStylianou, Marios. "Pharmaceutical And Immunollogical Challenge Of Fungal Pathogens". Doctoral thesis, 2015. http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-107713.
Pełny tekst źródłaKsiążki na temat "Repurposed drug"
Starving Cancer and Viruses with Commonly-Prescribed Pills: The Repurposed Drug Revolution. hope pressworks international, 2020.
Znajdź pełny tekst źródłaRepurposed Drugs for Cancer [Working Title]. IntechOpen, 2021. http://dx.doi.org/10.5772/intechopen.91884.
Pełny tekst źródłaSingh, Pankaj Kumar, Dharmendra Kumar Khatri, Shashi Bala Singh i Anitha Sriram, red. An Update on SARS-CoV-2: Damage-response Framework, Potential Therapeutic Avenues and the Impact of Nanotechnology on COVID-19 Therapy Volume 1. BENTHAM SCIENCE PUBLISHERS, 2022. http://dx.doi.org/10.2174/97898150398631220101.
Pełny tekst źródłaParihar, Suraj P., Shashank Gupta, Makram Essafi, Bibhuti Mishra i Ramandeep Singh, red. Repurposed Drugs as Immune- Modulators to Combat Infectious Diseases. Frontiers Media SA, 2022. http://dx.doi.org/10.3389/978-2-88974-370-4.
Pełny tekst źródłaCampos-Parra, Alma D., Carlos Pérez-Plasencia, Teresita Padilla-Benavides i Eduardo López-Urrutia, red. Repurposed Drugs Targeting Cancer Signaling Pathways: Clinical Insights to Improve Oncologic Therapies. Frontiers Media SA, 2021. http://dx.doi.org/10.3389/978-2-88971-239-7.
Pełny tekst źródłaHwang, Young-Hwan, i York Pei. Autosomal dominant polycystic kidney disease management. Redaktor Neil Turner. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199592548.003.0309_update_001.
Pełny tekst źródłaCampos-Parra, Alma D., Carlos Pérez-Plasencia, Teresita Padilla-Benavides i Eduardo López-Urrutia, red. Repurposed Drugs Targeting Cancer Signaling Pathways: Dissecting New Mechanisms of Action Through in vitro and in vivo Analyses. Frontiers Media SA, 2021. http://dx.doi.org/10.3389/978-2-88971-716-3.
Pełny tekst źródłaHudson, Dale. Terrorist Vampires: Religious Heritage or Planetary Advocacy. Edinburgh University Press, 2018. http://dx.doi.org/10.3366/edinburgh/9781474423083.003.0007.
Pełny tekst źródłaCzęści książek na temat "Repurposed drug"
Patil, Ruchira, Harshad Takate, Gaurav Shanbhag, Harshada Kiran Sonawane, Amruta Prabhakar Padakanti i Naveen Chella. "Clinical Trials on Repurposed Drugs: An Overview". W Drug Repurposing, 173–99. Singapore: Springer Nature Singapore, 2024. http://dx.doi.org/10.1007/978-981-97-5016-0_9.
Pełny tekst źródłaReaume, Andrew G., i Christopher A. Lipinski. "Chapter 10. Preclinical. A Repurposed Novel Lyn Kinase Activator, MLR-1023, is a Model Example of Pharmacological Pleiotropy". W Drug Repurposing, 196–220. Cambridge: Royal Society of Chemistry, 2022. http://dx.doi.org/10.1039/9781839163401-00196.
Pełny tekst źródłaChopra, Simran, Aditya Dahiya, Ashrit Nair, Navneet Sharma i Rakesh Kumar Sharma. "2-Deoxy-d-Glucose: A Repurposed Drug for COVID-19 Treatment". W Drug Repurposing for Emerging Infectious Diseases and Cancer, 479–500. Singapore: Springer Nature Singapore, 2023. http://dx.doi.org/10.1007/978-981-19-5399-6_20.
Pełny tekst źródłaDahiya, Mini, Anil Kumar, Monu Yadav, Pratibha Dhakla i Shiva Tushir. "Therapeutic Targeting of Antineoplastic Drugs in Alzheimer’s Disease: Discovered in Repurposed Agents". W Drug Repurposing for Emerging Infectious Diseases and Cancer, 329–45. Singapore: Springer Nature Singapore, 2023. http://dx.doi.org/10.1007/978-981-19-5399-6_15.
Pełny tekst źródłaGautam, Rupesh K., Ritu Mishra, Kanika Sharma i Manju Sharma. "Cellular and Molecular Mechanisms of Repurposed Antidiabetic Drug as an Adjunctive Treatment for Tuberculosis". W Targeting Cellular Signalling Pathways in Lung Diseases, 355–72. Singapore: Springer Singapore, 2021. http://dx.doi.org/10.1007/978-981-33-6827-9_15.
Pełny tekst źródłaCervantes, Duilio, i Aida Adlimoghaddam. "Repurposed Drugs". W Small Molecules in Neurodegeneration, 137–50. Boca Raton: CRC Press, 2025. https://doi.org/10.1201/9781003520610-8.
Pełny tekst źródłaArrowsmith, John, i Richard Harrison. "Drug Repositioning: The Business Case and Current Strategies to Repurpose Shelved Candidates and Marketed Drugs". W Drug Repositioning, 7–32. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2012. http://dx.doi.org/10.1002/9781118274408.ch1.
Pełny tekst źródłaMorasso, Stefano, Elisa Costanzi, Nicola Demitri, Barbara Giabbai i Paola Storici. "The Role of Structural Biology Task Force: Validation of the Binding Mode of Repurposed Drugs Against SARS-CoV-2 Protein Targets". W Exscalate4CoV, 51–59. Cham: Springer International Publishing, 2023. http://dx.doi.org/10.1007/978-3-031-30691-4_7.
Pełny tekst źródłaDhir, Neha, Ashish Jain, Dhruv Mahendru, Ajay Prakash i Bikash Medhi. "Drug Repurposing and Orphan Disease Therapeutics". W Drug Repurposing - Hypothesis, Molecular Aspects and Therapeutic Applications. IntechOpen, 2020. http://dx.doi.org/10.5772/intechopen.91941.
Pełny tekst źródłaT. Galatage, Sunil, Arehalli S. Manjappa, Raghwendra R. Waghmode, Swapnil S. Harale, Rushikesh B. Katkar, Sujit A. Desai, Swapnil S. Chopade i in. "Role of Drug Repurposing in Cancer Treatment and Liposomal Approach of Drug Targeting". W Drug Repurposing - Advances, Scopes and Opportunities in Drug Discovery [Working Title]. IntechOpen, 2023. http://dx.doi.org/10.5772/intechopen.110105.
Pełny tekst źródłaStreszczenia konferencji na temat "Repurposed drug"
Ding, Yi, Ruiyang Gong, Juzhen Bai, Ruizhi Ou i Zimeng Wu. "CTAG using GNN for GWAS analyses of schizophrenia to identify disease-associated genes and repurpose drugs". W 2024 Fourth International Conference on Biomedicine and Bioinformatics Engineering (ICBBE 2024), redaktorzy Pier Paolo Piccaluga, Ahmed El-Hashash i Xiangqian Guo, 21. SPIE, 2024. http://dx.doi.org/10.1117/12.3044175.
Pełny tekst źródłaCavalla, David. "Commercialising drug repurposed products: what works and what doesn’t". W RExPO24. REPO4EU, 2024. http://dx.doi.org/10.58647/rexpo.24010.
Pełny tekst źródłaEvankovich, J., J. Villandre, T. Lear, Y. Chen, F. Tuncer, V. White, D. Camarco, Y. Liu i B. Chen. "A Repurposed Drug Screen for Compounds Regulating Aquaporin 5 Stability in Lung Epithelial Cells". W American Thoracic Society 2021 International Conference, May 14-19, 2021 - San Diego, CA. American Thoracic Society, 2021. http://dx.doi.org/10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a4388.
Pełny tekst źródłaEvankovich, J., J. Villandre, V. White, T. Lear, Y. Chen, F. Tuncer, K. Lockwood, D. Camarco, Y. Liu i B. Chen. "A Repurposed Drug Screen for Compounds Regulating Aquaporin 5 Stability in Lung Epithelial Cells". W American Thoracic Society 2022 International Conference, May 13-18, 2022 - San Francisco, CA. American Thoracic Society, 2022. http://dx.doi.org/10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a3254.
Pełny tekst źródłaYadav, Anjali, Shraddha Bhutkar i Vikas Dukhande. "Metabolic Rewiring and Mechanism of Action of an Antiepileptic Drug Repurposed for its Potential in Glioblastoma". W ASPET 2023 Annual Meeting Abstracts. American Society for Pharmacology and Experimental Therapeutics, 2023. http://dx.doi.org/10.1124/jpet.122.291070.
Pełny tekst źródłaRabbani, Naila, Paul John Thornalley, Maryam Al-Motawa i Mingzhan Xue. "Vulnerabilities of the SARS-Cov-2 Virus to Proteotoxicity – Opportunity for Repurposed Chemotherapy of COVID-19 Infection". W Qatar University Annual Research Forum & Exhibition. Qatar University Press, 2020. http://dx.doi.org/10.29117/quarfe.2020.0291.
Pełny tekst źródłaPapineni, Rao V., Shahid Umar, Alexey Goltsov i Ishfaq Ahmed. "Abstract LB-012: Deoxyglucose and bisphosphonate shows common pathways in its drug repurposed anticancer and anti-infection actions". W Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.am2017-lb-012.
Pełny tekst źródłaFahal, AH, ES Ahmed, SM Bakhiet, OE Bakheet, LA Fahal, AA Mohamed, ESW Mohhamedelamin i in. "Once-weekly repurposed fosravuconazole versus daily itraconazole, with surgery, in patients with eumycetoma in Sudan: a randomised, double-blind, phase 2, proof-of-concept superiority trial". W MSF Scientific Days International 2024. NYC: MSF-USA, 2024. http://dx.doi.org/10.57740/jznxuiaji7.
Pełny tekst źródłaChakravarti, Sayak, Suman Mazumder, Farnaz Hemmati, Farshad Amiri, Taraswi Mitra Ghosh, Ujjal Kumar Mukherjee, Panagiotis Mistriotis i in. "Abstract 1354: Deciphering the functional basis of synergy between taxanes and TAK715: A novel repurposed drug candidate in treatment-refractory aggressive prostate cancer". W Proceedings: AACR Annual Meeting 2021; April 10-15, 2021 and May 17-21, 2021; Philadelphia, PA. American Association for Cancer Research, 2021. http://dx.doi.org/10.1158/1538-7445.am2021-1354.
Pełny tekst źródłaNeal, Tristan, Nanyun Tang, George Reid, Sara Byron, Harshil Dhruv i Michael Berens. "Abstract 2189: Evaluating efficacy of repurposed drugs in treatment of glioblastoma". W Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-2189.
Pełny tekst źródła